Organisation paid for research Program year 2025 Source: CMS Open Payments

Valley Health Systems

Neither a doctor nor a teaching hospital

Research payments

$269,900

74 payments

Through program year 2025, Valley Health Systems is reported as receiving $269,900 in research payments, across 74 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$32,340	17
2024	Research	$23,022	10
2023	Research	$39,944	8
2022	Research	$20,792	5
2021	Research	$55,077	12
2020	Research	$65,113	15
2019	Research	$33,612	7

Breakdown

Who paid Research payments · program years 2019–2025

Takeda Pharmaceuticals U.S.A., Inc. $186,884 52 payments
Shire North American Group Inc $33,612 7 payments
SK Life Science, Inc. $31,404 14 payments
Boston Scientific Corporation $18,000 1 payment

Studies the money was for Research payments · program years 2019–2025

A Phase 3 Long-Term Safety Extension Study of Shp647 in Subjects With Moderate to Severe Ulcerative Colitis (Aida) $108,570 31 payments
A Phase 3 Long-Term Safety Extension Study of Shp647 in Subjects With Moderate to Severe Ulcerative Colitis (Aida) $38,920 5 payments
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Shp647 As Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis Figaro UC 302 $24,183 4 payments
Ykp509c003 $19,079 10 payments
Fracture $18,000 1 payment
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Shp647 As Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (Figaro UC 302) $15,094 5 payments
Ykp3089c049 $12,325 4 payments
A Phase 3 Long-Term Safety Extension Study of Shp647 in Subjects With Moderate to Severe Ulcerative Colitis Aida $9,429 3 payments
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Shp647 As Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (Figaro UC 302) $7,565 3 payments
Study of the Effect of Shp647 As Maintenance Treatment in Participants With Moderate to Severe Ulcerative Colitis Who Achieved Clinical Response in Induction Studies $7,099 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.